tiprankstipranks
Advertisement
Advertisement
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal
PremiumCompany AnnouncementsDogwood Therapeutics Shareholders Approve Warrant Exercise Proposal
1M ago
Dogwood Therapeutics: Strengthened Capital Structure, Advancing Pain Pipeline, and Extended IP Support a Buy-Rated Risk-Reward Profile
Premium
Ratings
Dogwood Therapeutics: Strengthened Capital Structure, Advancing Pain Pipeline, and Extended IP Support a Buy-Rated Risk-Reward Profile
2M ago
Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
Premium
The Fly
Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
2M ago
Dogwood announces financing of up to $26.8M
PremiumThe FlyDogwood announces financing of up to $26.8M
3M ago
Dogwood announces interim Phase 2b trial results on Halneuron
Premium
The Fly
Dogwood announces interim Phase 2b trial results on Halneuron
4M ago
Dogwood files for IP protection for synthetic Halneuron
Premium
The Fly
Dogwood files for IP protection for synthetic Halneuron
4M ago
Dogwood reports Q3 EPS ($8.20) vs ($2.05) last year
PremiumThe FlyDogwood reports Q3 EPS ($8.20) vs ($2.05) last year
5M ago
Dogwood Therapeutics Announces Business Combination Plans
Premium
Company Announcements
Dogwood Therapeutics Announces Business Combination Plans
6M ago
Dogwood to present on Halneuron pain research program
Premium
The Fly
Dogwood to present on Halneuron pain research program
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100